CD274 and non-small cell lung carcinoma: Key phase III studies (Table 2) evaluating various anti-PD-(L)-1 drugs, either alone or in combination with chemotherapy, have established ICI as the primary first-line therapy for metastatic NSCLC without targetable genetic mutations.